Among them, MUC16 and MUC20 membrane-bound mucins and their combination MUC4/MUC16/MUC20 is associated with a poorer overall survival in different cancers including pancreatic, colon and stomach cancers suggesting MUC4/MUC16/MUC20 as a poor prognostic signature for these cancers. This evidence concerns the gene MUC20 and gastric neoplasm.